Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Solid Tumors

Aliases
solid tumors

236 clinical trials

338 products

24 drugs

Product
TNG260
Product
Pembrolizumab
Product
Ulevostinag
Clinical trial
An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-26
Product
Durvalumab
Product
MEDI9253
Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1 Open-label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Status: Completed, Estimated PCD: 2022-04-21
Clinical trial
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-06-24
Product
Topotecan
Product
Cyclophosphamide
Product
Palbociclib
Product
Temozolomide
Product
Irinotecan
Clinical trial
A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-01
Product
ADRX-0706
Product
JSI-1187
Product
Dabrafenib
Clinical trial
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-10-31
Product
INCB0123667
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Etoposide
Product
5fluorouracil
Product
Capecitabine
Product
CDX-585
Product
Tislelizumab
Product
Paclitaxel
Product
Carboplatin
Product
Ociperlimab
Product
Pemetrexed
Product
Nab paclitaxel
Product
Cisplatin
Product
Oxaliplatin
Product
Entrectinib
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Status: Active (not recruiting), Estimated PCD: 2025-06-15
Product
IBR854
Clinical trial
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Status: , Estimated PCD: 2024-06-30
Product
TAK-102
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR854 Cell Injection in Patients With Unresectable Locally Advanced Or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Product
TAK-103
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-27
Product
HF158K1
Clinical trial
A Multi-Regional, Open-Label, Dose Escalation and Dose Expansion Phase Ⅰ Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-23
Product
S-531011
Product
pembrolizumab
Clinical trial
A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-04-16
Product
HF159K1
Clinical trial
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2024-01-04
Product
Atezolizumab
Clinical trial
An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-α (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2024-01-18
Product
RO7296682
Product
RO7300490
Clinical trial
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2025-01-10
Product
AK127
Product
AK104
Clinical trial
A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-30
Product
Subasumstat
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-24
Product
Chemotherapy
Clinical trial
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-01
Product
KD6001
Clinical trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KD6001 in Combination With Tislelizumab±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-04-30
Product
Bevacizumab
Clinical trial
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
Avelumab
Product
ZG005
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS
Status: Completed, Estimated PCD: 2012-05-10
Product
PF-04449913
Product
INCA33890
Product
ICP-723
Clinical trial
A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CDX-1140
Product
AZD2281
Clinical trial
A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2009-02-06
Clinical trial
A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 in Subjects With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-31
Product
TXN10128
Product
CDX-301
Product
XNW5004
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Status: Recruiting, Estimated PCD: 2024-12-07
Product
Ponatinib
Clinical trial
An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2013-10-16
Clinical trial
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2025-01-07
Product
E7386
Clinical trial
An Open-label Phase 1 Study of E7386 in Subjects With Advanced Solid Tumor Including Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Product
CEP-9722
Clinical trial
An Open-label, Non-randomized Phase I Investigation of Human ADME (Absorption, Distribution, Metabolism and Excretion) and Absolute Oral Bioavailability of BI 907828 in Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-05-21
Product
[¹⁴C]-BI 907828 mixed with BI 907828
Product
BI 907828
Clinical trial
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Status: Completed, Estimated PCD: 2023-09-13
Product
ARX788
Clinical trial
A Multicenter, Open-label, Phase 1a/b Study of HC-7366 in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-09
Product
HC-7366
Product
BI 1703880
Product
Ezabenlimab
Product
Olaparib
Clinical trial
A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Status: Active (not recruiting), Estimated PCD: 2025-07-24
Clinical trial
An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7296682, A CD25-Targeting, T-Regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumor
Status: Terminated, Estimated PCD: 2022-07-21
Product
RLY-4008
Clinical trial
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
CX-904
Clinical trial
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Osimertinib
Product
IBR854 Cell
Product
Eciskafusp Alfa
Clinical trial
A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
An Open-Label, Multicenter, Randomized, Dose-Escalation and Extension, Phase IA/IB Study to Evaluate Safety and Anti-Tumor Activity of RO7284755, A PD-1 Targeted IL-2 Variant (IL-2V) Immunocytokine, Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-07
Clinical trial
Exploratory, Open Label Study to Improve Function and Welfare of Late-stage Cancer Subjects by Amorphous Calcium Carbonate (ACC) Treatment, Administered Orally and Concomitantly With Inhalation
Status: Terminated, Estimated PCD: 2019-12-31
Product
Amorphous Calcium Carbonate
Product
IK-930
Clinical trial
A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients With Advanced Solid Tumor.
Status: Recruiting, Estimated PCD: 2025-03-30
Product
QTX3034
Clinical trial
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Status: Recruiting, Estimated PCD: 2027-04-01
Product
TCC1727
Clinical trial
My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Status: Completed, Estimated PCD: 2023-05-24
Product
Pertuzumab
Product
Erlotinib
Product
Vemurafenib
Product
Cobimetinib
Product
Vismodegib
Product
Alectinib
Product
Cetuximab
Product
RMC-5552
Clinical trial
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Product
Axitinib
Product
Utomilumab
Product
ASP9801
Clinical trial
A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
BL-M07D1
Product
Lomvastomig
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Initial Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
cediranib
Product
CMP 001
Product
PF04518600
Clinical trial
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2009-07-30
Product
BI 1701963
Clinical trial
A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
Trametinib
Clinical trial
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2019-02-19
Product
Paclitaxel + Docetaxel + Carboplatin + Cisplatin
Product
Pegilodecakin
Product
gemcitabine/nab-paclitaxel
Clinical trial
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Status: Recruiting, Estimated PCD: 2043-08-04
Product
Lenvatinib
Product
FOLFOX
Clinical trial
A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Docetaxel
Product
Sacituzumab Govitecan-Hziy
Product
GS-9716
Product
Standard of Care
Product
RO7247669
Clinical trial
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
Status: Recruiting, Estimated PCD: 2025-09-08
Product
Talazoparib
Product
Bemarituzumab
Product
Lorlatanib
Product
Keytruda
Product
INCB161734
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Retifanlimab
Product
ABBV-303
Product
Budigalimab
Clinical trial
A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination With Budigalimab (ABBV-181), in Adult Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-01-19
Product
STX-478
Product
Fulvestrant
Product
Lenvatinib + Envafolimab
Clinical trial
Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-28
Product
Sunitinib
Clinical trial
A Phase 2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With Ezabenlimab in Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-05-03
Product
ezabenlimab
Product
HC-5404-FU
Product
BI 1831169
Clinical trial
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-01
Product
midazolam
Clinical trial
A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-12-07
Product
Avapritinib
Product
Ifinatamab deruxtecan
Clinical trial
An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Itraconazole
Product
Autogene cevumeran
Product
Rifampicin
Clinical trial
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
GS-9911
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-01
Product
nivolumab
Product
Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Product
Pazopanib
Clinical trial
A Phase Ia/Ib, Open-label, Multicentre Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumours Expressing KRAS G12C Mutation
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TAK-853
Product
E7130
Clinical trial
A Phase 1 Study of E7130 in Subjects With Solid Tumor
Status: Recruiting, Estimated PCD: 2025-06-30
Product
VB10.NEO
Clinical trial
A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-033 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
ICP-033
Product
BL-B01D1
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Encorafenib
Product
Encorafenib & Binimetinib
Product
Encorafenib & Binimetinib & Ribociclib
Product
Encorafenib + Binimetinib + Cetuximab
Product
Binimetinib
Product
Gemcitabine/carboplatin
Product
Midazolam
Product
Zimberelimab
Product
BAY1436032
Clinical trial
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Product
Fludarabine
Product
BI 1821736
Clinical trial
An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-tumor Activity in Patients With IDH1-R132X-mutant Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2018-11-08
Product
Idasanutlin
Product
Venetoclax
Product
Cytarabine
Product
Intrathecal Chemotherapy
Clinical trial
An Open-label, Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-11-22
Product
ES102
Clinical trial
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
JAB-30355
Clinical trial
An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 Administered as a Single Agent in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-01
Clinical trial
A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients With Recurrent or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-03-09
Product
Nivolumab
Product
Regorafenib
Product
BI 1823911
Product
Dazostinag
Clinical trial
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-15
Product
Platinum
Product
5-fluorouracil
Clinical trial
An Open-label, Phase I Dose Escalation Followed by Dose Expansion Trial in Patients With Advanced Solid Tumours to Investigate Safety, Pharmacokinetics, and Efficacy and to Select the Dose for Further Development of BI 770371 in Combination With Ezabenlimab
Status: Recruiting, Estimated PCD: 2024-07-19
Product
BI-1910
Clinical trial
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-14
Clinical trial
A Phase II, Open Label, Randomized, Non-Comparative Cohorts Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
Status: Recruiting, Estimated PCD: 2028-10-20
Product
Tiragolumab
Clinical trial
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Status: Recruiting, Estimated PCD: 2032-09-25
Product
Ipatasertib
Product
Trastuzumab emtansine
Product
Belvarafenib
Product
Pralsetinib
Product
Inavolisib
Clinical trial
Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study
Status: Completed, Estimated PCD: 2011-08-01
Clinical trial
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Therapy in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-31
Product
Letrozole
Product
CTS2190
Product
[¹⁴C]-BI 907828
Product
Selinexor
Clinical trial
Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Status: Recruiting, Estimated PCD: 2025-03-01
Product
XmAb24306
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
AZD9150
Clinical trial
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Status: Active (not recruiting), Estimated PCD: 2020-02-28
Product
Tremelimumab
Clinical trial
A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2027-06-01
Product
RMC-6236
Product
HRS-4642
Clinical trial
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Product
Temodar
Clinical trial
Expanded Access Program (EAP) for Avapritinib
Status:
Clinical trial
Phase I Study to Evaluate the Safety ,Tolerability, and Pharmacokinetics of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With BI 3011441 in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours
Status: Terminated, Estimated PCD: 2022-01-18
Product
BMS-986156
Clinical trial
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-12-16
Product
KAZ954
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-09-15
Product
NIR178
Product
NZV930
Clinical trial
Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2020-05-12
Clinical trial
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, and Pharmacokinetics of INCB086550 in Japanese Participants With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-05-13
Product
IDX-1197
Product
GT101
Clinical trial
A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-08-24
Clinical trial
A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2022-06-30
Product
PDR001
Clinical trial
A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Completed, Estimated PCD: 2022-02-04
Product
Relacorilant
Clinical trial
An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies
Status: Terminated, Estimated PCD: 2022-05-18
Product
E7389-LF
Clinical trial
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2011-10-26
Clinical trial
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
TAS0953/HM06
Clinical trial
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Status: Recruiting, Estimated PCD: 2025-03-01
Product
MEGF0444A
Product
RO7444973
Product
Tocilizumab
Clinical trial
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2021-09-24
Clinical trial
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2014-01-06
Product
gemcitabine
Product
carboplatin
Clinical trial
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2021-09-01
Product
M3814
Clinical trial
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Status: Terminated, Estimated PCD: 2021-02-01
Clinical trial
A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-21
Clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2020-08-31
Product
RAIN-32
Clinical trial
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients With Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Product
M6620
Clinical trial
A Rollover Study to Provide Continued Treatment With M6620
Status: Active (not recruiting), Estimated PCD: 2023-12-15
Product
Farletuzumab
Product
CDX-527
Product
IBI188
Product
Paclitaxel + Carboplatin
Clinical trial
An Exploratory Study of A-337 in the Management of Malignant Solid Dose
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
APS03118
Clinical trial
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2020-07-14
Product
VAL-413
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-09-30
Clinical trial
Assessment of Prospective Real-world Outcomes Based on Single-patient Protocol Data Collection of Afatinib (GILOTRIF®) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions
Status:
Product
TRX518
Clinical trial
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Status: Terminated, Estimated PCD: 2019-09-02
Clinical trial
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07224826, AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Withdrawn, Estimated PCD: 2026-04-14
Product
INCB086550
Product
Adavosertib
Clinical trial
A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid Tumor
Status: Terminated, Estimated PCD: 2011-06-15
Product
CDDP
Product
BGB-B167
Clinical trial
Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2022-07-30
Product
Cisplatin/Carboplatin
Product
Sintilimab
Clinical trial
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Chinese Patients With Selected Advanced or Metastatic Solid Tumors
Status: Withdrawn, Estimated PCD: 2025-03-01
Product
ASP0739
Clinical trial
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
Status: Completed, Estimated PCD: 2023-06-01
Product
BI 770371
Clinical trial
A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
Runimotamab
Clinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-21
Product
GDC-6036
Product
Camonsertib
Product
Epoetin
Product
IBI363
Product
SYH2051
Product
ARTS-021
Clinical trial
A Multi-center, Open-label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS2190 in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Sitravatinib
Product
Enfortumab Vedotin
Product
Ipilimumab
Clinical trial
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-04-19
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Product
CRTE7A2-01
Product
FOLFIRI
Clinical trial
A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Acasunlimab
Product
MEDI4736
Product
AZD5069
Product
RMC-6291
Product
CTO
Product
BI 3011441
Clinical trial
A Phase 1b Study of ARQ 751 as a Single Agent or in Combination With Other Anti-cancer Agents in Adult Subjects With Advanced Solid Tumors With PIK3CA / AKT / PTEN Mutations
Status: Terminated, Estimated PCD: 2021-03-10
Product
Vevorisertib
Clinical trial
A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Product
JAB-3312
Clinical trial
A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
Status: Completed, Estimated PCD: 2021-09-27
Product
TALZENNA
Clinical trial
A Phase I Open-label Trial of BI 3011441 in Japanese Patients With NRAS/KRAS Mutation Positive Advanced, Unresectable or Metastatic Refractory Solid Tumours
Status: Completed, Estimated PCD: 2022-10-13
Product
BAY94-9343
Product
MEDI1191
Clinical trial
An Open-label, Multi-center, Phase 1b/2a Basket Trial of IDX-1197 in Patients With Homologous Recombination Repair Mutated Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
LHC165
Product
PM534
Clinical trial
A Multicenter, Open-label, Phase Ib/II Study on the Efficacy and Safety of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-22
Clinical trial
A Phase I Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Patients With Locally Advanced Or Metastatic Solid Tumors.
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
An Open-label, Phase I Multicenter, Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Checkpoint Inhibitor Monotherapy in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Completed, Estimated PCD: 2021-07-21
Product
F520
Product
NECVAX-NEO1
Product
Telaglenestat
Clinical trial
An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-12
Clinical trial
An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Product
JAB-2485
Clinical trial
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2022-01-24
Product
ADG106
Clinical trial
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Status: Completed, Estimated PCD: 2021-01-31
Product
Tomivosertib
Product
INCB001158
Clinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-30
Product
adavosertib
Product
cisplatin
Product
TIL
Product
KPT-9274
Product
Niacin ER
Product
APL-101
Product
ON123300
Clinical trial
A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Status: Recruiting, Estimated PCD: 2024-07-19
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients With Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
Status: Recruiting, Estimated PCD: 2025-02-01
Product
KT-333
Clinical trial
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APS03118 in Adult Patients With Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Recombinant Anti-EpCAM-CD3 Antibody
Product
XmAb662
Clinical trial
A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2022-10-26
Product
DF6002
Product
afatinib
Product
PF-07224826
Product
M3541
Product
5-FU
Product
GM-CSF
Clinical trial
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Phase 1b Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2021-03-19
Product
ICVB-1042
Product
IDE196
Product
Crizotinib
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-11-28
Clinical trial
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS
Status: Completed, Estimated PCD: 2023-08-14
Clinical trial
A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-31
Product
IBI334
Product
VP301
Clinical trial
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC98 For Injection in Subjects With Advanced Malignant Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-12-28
Clinical trial
An Open-Label, Phase 1 Trial to Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Status: Completed, Estimated PCD: 2023-11-02
Clinical trial
The Effects of Ginseng on Cancer-Related Fatigue
Status: Active (not recruiting), Estimated PCD: 2016-05-15
Product
Panax Ginseng
Clinical trial
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Status: Completed, Estimated PCD: 2019-06-01
Clinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070
Drug
Gemcitabine
Clinical trial
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors
Status: Completed, Estimated PCD: 2015-09-08
Product
Recombinant human interleukin-15
Product
NK Cell Infusion
Clinical trial
Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
MET-4
Clinical trial
A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2027-03-05
Drug
PF-07220060
Clinical trial
A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Completed, Estimated PCD: 2024-02-22
Product
TALIMOGENE LAHERPAREPVEC
Clinical trial
The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer
Status: Active (not recruiting), Estimated PCD: 2021-02-28
Product
Dexamethasone
Product
Placebo
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-10-15
Product
GSK5733584
Clinical trial
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
ETC-1922159
Clinical trial
A Phase I/II Study For the Use of White Blood Cells From Healthy Donor-participants To Treat Subjects With Solid Cancers
Status: , Estimated PCD: 2026-12-01
Product
White Blood Cells
Clinical trial
A Single-Arm Pilot Study of Adjuvant Pembrolizumab in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Gedatolisib
Clinical trial
A Phase IB/II Clinical Study on the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Medication in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Drug
Adebrelimab
Drug
SHR-A1921
Clinical trial
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
Status: Completed, Estimated PCD: 2023-02-07
Drug
SX-682
Product
M7824
Product
MVA-BN-CV301
Clinical trial
A MulticenterOpen LableDose Escalat Tion and Dose Expansion Clinical Study to Evaluate the Safety, Tolerance and Ini Itial Effectiveness of WTX212A Injection in Patients With Unresectable or Metasta Atic Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-08-30
Product
WTX212A
Clinical trial
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Drug
V940
Drug
mFOLFOX6
Product
SoC Treatment
Clinical trial
An Non-randomized Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy of BA1106 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
BA1106
Clinical trial
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Status: Recruiting, Estimated PCD: 2038-04-30
Product
Rimiducid
Product
TROP2-CAR-NK Cells
Drug
fludarabine
Drug
cyclophosphamide
Clinical trial
A Multicenter, Open-label, Multi-cohort Phase Ib Trial Evaluating the Efficacy and Safety of TQB2928 Injection Combined With Anlotinib Hydrochloride Capsule in Relapsed/Metastatic Osteosarcoma and Other Relapsed/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
TQB2928
Clinical trial
A Phase I Study of Ixazomib and Erlotinib in Advanced Solid Tumor Patients
Status: Completed, Estimated PCD: 2022-12-07
Product
Ixazomib
Drug
Erlotinib
Clinical trial
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Completed, Estimated PCD: 2017-12-18
Drug
Atezolizumab
Clinical trial
A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)
Status: Recruiting, Estimated PCD: 2025-01-31
Drug
bevacizumab
Product
erlotinib
Clinical trial
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial
Status: Withdrawn, Estimated PCD: 2025-07-01
Drug
pembrolizumab
Drug
Sitravatinib
Clinical trial
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
Status: Recruiting, Estimated PCD: 2027-03-11
Drug
cetuximab
Clinical trial
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2013-05-01
Product
Cabozantinib
Drug
Varlilumab
Clinical trial
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Recruiting, Estimated PCD: 2025-12-01
Product
INBRX-109
Drug
AN0025
Drug
Cisplatin
Clinical trial
Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-08-03
Product
Ceramide NanoLiposome
Clinical trial
A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-10
Product
JNJ-79032421
Clinical trial
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma
Status: Terminated, Estimated PCD: 2021-07-27
Clinical trial
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2014-02-27
Product
AMG 386
Product
MK-8353
Product
Selumetinib
Product
LXH254
Clinical trial
A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Status: Terminated, Estimated PCD: 2022-02-18
Product
SYD985
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With Relapsed or Refractory Multiple Myeloma, Lymphoma, or Solid Tumors
Status: Terminated, Estimated PCD: 2023-06-19
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-11-17
Clinical trial
A Single-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A French Non-interventional Prospective Multicenter Study Evaluating Quality of Care Perception of Cancer Patients Treated by Immunotherapy at Home - SATISFACT-HOME
Status: Recruiting, Estimated PCD: 2025-02-28
Product
5-Fluorouracil
Product
ORIC-114
Product
Immunotherapy
Product
Leucovorin
Product
Gemcitabine
Product
MASCT-I
Product
Sotatercept
Clinical trial
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Terminated, Estimated PCD: 2012-09-18
Clinical trial
A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2019-01-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2021-11-12
Product
Enapotamab vedotin
Product
axitinib
Product
crizotinib
Product
RC98
Product
Tisotumab Vedotin
Clinical trial
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2023-10-02
Product
LMP744
Clinical trial
An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-30
Product
IMP321
Clinical trial
Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-06
Product
Sacituzumab tirumotecan
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors
Status: Completed, Estimated PCD: 2017-11-01
Product
PD-0325901
Clinical trial
A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2019-09-19
Product
MG1MA3
Product
AdMA3
Product
Enzalutamide
Clinical trial
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Product
BAT7104
Clinical trial
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-27
Product
Nilotinib + Paclitaxel
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL008.16, a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody, in Patients With Advanced or Metastatic Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
FTL008.16
Clinical trial
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
ASTX660
Clinical trial
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2021-10-06
Product
SL-801
Clinical trial
A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Status: Active (not recruiting), Estimated PCD: 2018-07-20
Drug
durvalumab
Drug
tremelimumab
Clinical trial
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
Chimeric receptor T-cells + Trastuzumab
Product
Fludarabine and Cyclophosphosphamide
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Autologous, engineered T Cells targeting TP53 R175H
Clinical trial
A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells
Product
Recombinant Fowlpox Viral (FPV)-CV301
Clinical trial
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours
Status: Recruiting, Estimated PCD: 2025-06-17
Product
brigimadlin
Clinical trial
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults
Status: Terminated, Estimated PCD: 2022-10-01
Product
Lyso-thermosensitive liposomal doxorubicin
Clinical trial
Imaging of Solid Tumors Using FAP-2286
Status: Recruiting, Estimated PCD: 2024-06-30
Product
FAP-2286
Clinical trial
A Phase 1, Multicenter, Open-label Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Product
IBI3005
Clinical trial
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-17
Product
LCAR-C18S
Clinical trial
Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients With Advanced Solid Tumors Refractory to Standard Therapy
Status: Completed, Estimated PCD: 2020-05-12
Product
Everolimus
Clinical trial
A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2026-12-29
Product
PF-07220060 + PF-07104091 combination
Product
PF-07220060 + PF-07104091
Product
PF-07104091 + PF-07220060 + Fulvestrant
Product
PF-07104091 + PF-07220060 + Letrozole
Clinical trial
A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Lyso-thermosensitive Liposomal Doxorubicin
Clinical trial
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
Status: Recruiting, Estimated PCD: 2028-05-01
Product
Blood sampling
Product
Dasatinib
Clinical trial
Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors
Status: Completed, Estimated PCD: 2021-11-30
Product
ISA 101
Drug
T-VEC
Product
CFT1946
Clinical trial
A Phase I, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-01-31
Product
Iso-Fludelone
Clinical trial
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Status: Completed, Estimated PCD: 2022-05-23
Product
MSB0011359C
Clinical trial
A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR
Status: Completed, Estimated PCD: 2016-02-22
Product
Gefitinib + BKM120
Clinical trial
Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Status: Active (not recruiting), Estimated PCD: 2019-05-07
Clinical trial
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies
Status: Completed, Estimated PCD: 2023-05-04
Product
Afatinib
Drug
fluorouracil
Drug
mFOLFOXIRI
Product
TMZ
Clinical trial
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Status: , Estimated PCD: 2035-04-01
Product
anti-CD19 CAR
Drug
Trastuzumab
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2